Pharmafile - Research and Development News
Janssen, part of Johnson & Johnson, has announce new long-term data from its CHRYSALIS study, which assessed Rybrevant (amivantamab) in patients...
Netris Pharma has announced that it has dosed its first patient in the Lap-NET1 study for the safety and efficacy of anti-netrin-1 antibody NP137 in...
AbbVie has shared that upadacitinib (Rinvoq) has been shown to be effective in treating patients with moderately-to-severely-active systemic lupus...
Novo Nordisk has announced headline results from the phase 3b PIONEER PLUS trial for the safety and efficacy of once-daily oral semaglutide 25mg and...
GSK has announced promising results from part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) alongside standard-of-...
Novartis has announced positive results from its phase 3 NATALEE trial assessing Kisqali (ribociclib) along with endocrine therapy (ET) in patients...
US-based Biogen has announced two decisions the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee made surrounding its ALS drug,...
Kite has announced the primary overall survival (OS) analysis results of a phase 3 study into Yescarta for the treatment of adult patients with...
A new drug to treat ovarian cancer is set to enter the phase 3 UP-NEXT trial imminently. Upifitamab rilsodotin is an antibody-drug conjugate (...
Faron Pharmaceuticals, a clinical stage biopharmaceutical company, has revealed positive FDA feedback and recommendations for its monotherapy for...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
